Can BioAtla’s Oz-V set a new standard in ROR2-targeted therapy for head and neck cancer?
BioAtla and GATC Health advance Ozuriftamab Vedotin into a Phase 3 trial for OPSCC via SPV financing. Discover how this targets cancer and aging together.
Pharma & Biotech